Glofitamab results in cost savings versus epcoritamab in relapsed/refractory diffuse large B-cell lymphoma: a total cost of care analysisFootnote‡

Abstract

Fixed-treatment duration glofitamab and treat-to-progression epcoritamab are approved in the US for diffuse large B-cell lymphoma (DLBCL) after ≥2 prior therapies. An economic model was developed to estimate the per-patient total cost of care (TCC) for glofitamab versus epcoritamab from a US healthcare perspective. Treatment costs were based on time-to-off-treatment (glofitamab, NCT03075696) and progression-free survival (epcoritamab, NCT03625037). Per-patient cost savings, adjusted to 2023 US dollars, were observed with glofitamab versus epcoritamab across cycles 1–3 (−$56,275), and over 6 months (−$37,982), 1 year (−$68,195), 5 years (−$223,692), 10 years (−$325,175), and lifetime (−$503,075). While adverse event ($364) and treatment administration ($8,398) costs were higher for glofitamab versus epcoritamab, these were offset by consistently lower glofitamab treatment costs across all time horizons. Glofitamab showed per-patient TCC savings versus epcoritamab at every cumulative cycle and across all time horizons investigated, offering greater budget predictability and cost savings at the healthcare system and population levels.